Heidi Hau, PhD, leads business and scientific activities in the US including development strategies, external partnerships and CRO organization and execution. Previously, she’s led cross-functional R&D and translational biology programs across pharma, biotech startups and Fortune 500 companies. She’s worked across scientific and business development groups and directed global external innovation leading technical due diligence for external partnerships that focused on microbiological and molecular-based technologies. Most recently, she led key initiatives to expand investigational microbiota-based drug platforms for the treatment of infections and chronic diseases. As part of this role, she managed investigator-sponsored clinical studies and the led the Translational Biology team responsible for integration of microbiome basic research, discovery and clinical research enabling new or improved scientific understanding of microbiota-based therapeutics and/or assessment of new pipeline opportunities.
Microbial Profiling Showcase:
Innovating at the forefront of microbiome science, we operate as an extension of our clients' research organizations. At Clinical Microbiomics, we work broader, analyze deeper, and connect the dots to help researchers find the answers they need to impact health and disease.
Strain tracking shows cross-generational engraftment after FMT
Engraftment analysis shows that strains are transferred from FMT donor to pregnant recipient and baby.
The PMWC 2023 Microbial Profiling Showcase will provide a 15-minute time slot for selected companies in the Microbiome and Pathogen ID fields. The human microbiome is composed of a wide variety of microorganisms that are essential for maintaining human health and preventing disease. Research in this area is accelerating due to the rapid development in genome sequencing technologies. This showcase will present some of the leading companies in microbial profiling and pathogen identification.